Tue Jul 24 01:54:11 200717

Fetching...
 
YOU ARE HERE: Homepage > Newsdesk > Article
South Korean cloning scientist looking overseas-report
11 Jun 2007 01:35:16 GMT
Source: Reuters
SEOUL, June 11 (Reuters) - South Korea's disgraced stem cell scientist Hwang Woo-suk, who is on trial for criminal fraud, is in Thailand to discuss joining an international consortium for human embryonic stem cell research, a news report said on Monday.

Hwang, once celebrated as a national hero after raising hopes that his work could one day lead to cures for such illnesses as diabetes and spinal cord injuries, was indicted in May last year on charges of fraud and embezzlement related to his research.

"Doctor Hwang has said he would visit Thailand at the invitation of two research institutes, including a national university, and planned to look at international stem cell research's situation," the Maeil Business Newspaper quoted a government official as saying.

South Korea's Science Ministry, which previously oversaw Hwang's work, could not immediately confirm the report.

Hwang is testing the possibility of joining an international study on stem cell, possibly including a U.S. biomedical firm, because it had become impossible for him to secure human ova at home for research, the official was quoted as saying.

South Korea revoked Hwang's research licence last year, barring him from obtaining human eggs.

Hwang is accused of masterminding the fabrication of lab data for two landmark papers on cloning embryonic stem cells, which have since been retracted. He also is charged with fraud to secure funds and misusing state and private funds.

Prosecutors have also said he violated bioethics laws in procuring human eggs for research. He faces up to 10 years in jail if convicted on the fraud charges and three years for bioethics law violations.
AlertNet news is provided by

Delicio.us  |   Digg  |   NewsVine  |   Reddit                                                                                  Permalink
Thumb for /thefacts/imagerepository/RTRPICT/2007-07-19T233104Z_01_PHI03_RTRIDSP_2_USA-INFLUENZA_mainimage.jpg|/thenews/pictures/PHI03.htm
Thumb for /thefacts/imagerepository/RTRPICT/2007-07-19T232942Z_01_PHI05_RTRIDSP_2_USA-INFLUENZA_mainimage.jpg|/thenews/pictures/PHI05.htm
Thumb for /thefacts/imagerepository/RTRPICT/2007-07-19T232817Z_01_PHI06_RTRIDSP_2_USA-INFLUENZA_mainimage.jpg|/thenews/pictures/PHI06.htm
Thumb for /thefacts/imagerepository/RTRPICT/2007-07-19T232658Z_01_PHI04_RTRIDSP_2_USA-INFLUENZA_mainimage.jpg|/thenews/pictures/PHI04.htm
Thumb for /thefacts/imagerepository/RTRPICT/2007-07-19T232537Z_01_PHI07_RTRIDSP_2_USA-INFLUENZA_mainimage.jpg|/thenews/pictures/PHI07.htm

A technician illuminates eggs in the candling area of the Sanofi Pasteur influenza vaccine manufacturing facility during a simulation of the vaccine production process in Swiftwater, Pennsylvania, July 19, 2007. Influenza vaccine maker Sanofi Pasteur unveiled a factory on Wednesday that will eventually triple its production of the vaccine as U.S. officials seek to boost output amid fears of a pandemic.



URL: http://www.alertnet.org/thenews/newsdesk/SEO137778.htm

For our full disclaimer and copyright information please visit http://www.alertnet.org